Allergen-specific immunotherapy for feline atopic dermatitis offers the possibility of long-term disease modification rather than only symptom management.
Immunotherapy for feline atopic dermatitis represents the highest aspiration of allergy management: treating the underlying immune dysregulation rather than perpetually managing symptoms. A cat who achieves good ASIT response may reduce or eliminate the need for chronic immunosuppressive medication, with associated welfare benefits from reduced drug side effects. The welfare investment of the 6-12 month induction period, during which response may be incomplete, pays long-term dividends for cats who respond. For the 30-40% who do not respond adequately, knowing this at 12 months allows refocusing on symptomatic management.